Asset Details
Do you wish to reserve the book?
Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study
Do you wish to request the book?
Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study
2014
Overview
Respiratory syncytial virus is a common cause of illness and hospitalization, especially among infants and immunocompromised persons, but there are no accepted antiviral therapies. In this RSV challenge study, GS-5806, a new compound, showed activity against RSV.
Respiratory syncytial virus (RSV) infection accounts for substantial morbidity and mortality among infants
1
–
7
and is the most common reason for hospitalization of infants in the United States,
8
with an even greater outpatient burden of disease. Estimates indicate that among children younger than 2 years of age, the annual rate of RSV-related hospitalization is 5.2 per 1000, the rate of emergency department encounters is 32 to 57 per 1000, and the rate of outpatient visits is 66 to 177 per 1000.
2
Among infants younger than 1 year of age, the risk of death from respiratory causes is increased by a . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Alanine
/ Antiviral Agents - adverse effects
/ Antiviral Agents - pharmacokinetics
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Female
/ Humans
/ Male
/ Pyrazoles - pharmacokinetics
/ Respiratory Syncytial Virus Infections - drug therapy
/ Respiratory Syncytial Virus Infections - virology
/ Respiratory Syncytial Viruses
/ Sulfonamides - adverse effects
/ Sulfonamides - pharmacokinetics
/ Sulfonamides - therapeutic use
/ Viral diseases of the respiratory system and ent viral diseases
/ Viruses
